Loading company…
Neuregen develops gene therapies for neurological diseases using cell transdifferentiation and gene replacement.
Founded in 2021 and based in Suzhou, China, Neuregen develops gene therapy drugs using in-situ cell transdifferentiation and genetic replacement technologies. Its pipeline focuses on neurological conditions, including blinding eye diseases, difficult-to-treat neurological tumors and neurodegenerative diseases. In May 2026, it closed nearly CNY 100 million in Series A funding led by Wuhan High-tech Industry Investment Private Fund Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in